Why Prescription Drugs Cost 3x More in America

Ask why are prescription drugs so expensive here and you will be handed a story about research. American prices fund innovation. The rest of the world free-rides on our willingness to pay.

There is something in it. It is also not the mechanism. The mechanism is that every other rich country put a single large buyer across the table from the seller, and the United States did not. What we built instead is a chain of intermediaries, each of whom profits from the list price being high.

How much more do Americans actually pay?

Enough that medical tourism is a rational financial plan.

RAND's comparison of U.S. prices against 32 other OECD nations, prepared for HHS, put average U.S. prices at roughly 2.5 to 3 times the comparison-country average across all drugs. Narrow it to brand-name products and the gap widens considerably. Generics run the other way. U.S. generic prices sit at or below international levels, which matters for the rest of this argument.

The American drug pricing problem sits in one place: the products where a single seller faces no organized buyer.

What does a pharmacy benefit manager do to your price?

It sits between the manufacturer and you, and its revenue is tied to the number you are trying to lower.

A pharmacy benefit manager negotiates on behalf of insurers and employers. It builds the formulary (the list of which drugs your plan covers and at what tier) and extracts rebates from manufacturers in exchange for favorable placement. The Federal Trade Commission has reported that the three largest PBMs handle roughly 80% of U.S. prescriptions, and that the largest of them own insurers and pharmacy chains outright.

Here is the loop. A manufacturer wants tier-two placement. It raises the list price and offers a larger rebate off that inflated number. The PBM keeps a share. The plan sees a discount. And your coinsurance, if your plan calculates it as a percentage, gets calculated against the list price, the fictional one, rather than the rebated price anyone actually paid.

That is the part that turns a pricing problem into a design problem. Nobody in the chain is committing fraud. Everyone is responding to an incentive that rewards a high sticker.

Why did Medicare spend 19 years unable to negotiate?

Because Congress wrote it into law and left it there.

The 2003 Medicare Modernization Act created Part D and included a non-interference clause: the Secretary of Health and Human Services was barred from negotiating drug prices directly with manufacturers. The largest single purchaser of prescription drugs in the country was legally required not to act like one.

That held for 19 years, until the Inflation Reduction Act of 2022 allowed negotiation for a limited, phased-in list of high-spend drugs and capped insulin at $35 a month for Medicare beneficiaries. The same law introduced an annual out-of-pocket cap on Part D spending. Real changes, and narrow ones. They apply to Medicare, to selected drugs, on a schedule. If you are 34 with an employer plan and a specialty prescription, none of it reaches you.

Why don't patents expire and fix this?

They do, eventually. The system is built to make eventually take a long time.

A drug patent grants a period of exclusivity to reward the risk of development. That is the bargain and it is defensible. What is harder to defend is what happens as the clock runs down: manufacturers file additional patents on delivery mechanisms, dosages, formulations, and manufacturing methods, layering protections that extend the effective monopoly well past the original molecule's term. Researchers call the result a patent thicket. Litigation over these secondary claims can delay a generic entrant by years.

For biologics the barrier is higher still. Biosimilars are expensive and slow to develop and cannot be substituted as freely as chemical generics, so competition arrives late and shaves less off the price when it does.

What happens when people cannot afford the prescription?

They stop taking it, and the system pays more later.

KFF's health tracking polling keeps finding that roughly 3 in 10 adults report not taking a medication as prescribed at some point in the past year because of cost: skipping doses, cutting pills, delaying a refill, or never filling it at all. That is what a routine adaptation to a price looks like at scale.

Rationing insulin, splitting a blood pressure tablet, or stretching an inhaler produces a predictable set of outcomes: the emergency visit, the admission, the complication that costs an order of magnitude more than the drug would have. The savings are personal and immediate. The costs are collective and delayed, which is exactly the kind of trade a fragmented system is worst at seeing.

Who is this expensive for?

Not everyone equally, and that is the design.

If you are on Medicare with insulin, your cost is capped. If you have a low-deductible employer plan with flat copays, a brand-name drug might cost you $40. If you are in a high-deductible health plan in March, you are paying the full negotiated rate, and if your plan uses coinsurance you may be paying a percentage of a list price nobody actually pays. Same drug, same pharmacy, four different prices depending on paperwork.

The people rationing are concentrated at the bottom of that distribution. A full-time worker at the $7.25 federal minimum wage, unchanged since 2009, earns about $15,000 a year before taxes. A single specialty prescription can exceed a month of that. Roughly 100 million Americans carry healthcare debt totaling near $220 billion (KFF, 2024), and prescriptions are a steady contributor to it, one refill at a time.

The price is a policy, not a market

Nothing about American drug prices is natural. Every other wealthy country produces a lower number by putting a real buyer opposite the seller: a national formulary, a reference price, or a health technology assessment body with the power to say no. We chose a chain of intermediaries whose margins scale with the list price, then told patients to shop.

The Inflation Reduction Act proved the arrangement is changeable. Nineteen years of non-interference ended with a vote, and prices for selected drugs moved. What it did not do is reach the uninsured, the underinsured, or the worker whose deductible resets every January.

A drug you cannot afford is medically identical to a drug that does not exist. The gap between those two things is filled by income, which is why this ends where the rest of it does, with a wage floor that has not moved in over fifteen years while every price attached to staying alive has. The full accounting is in medical debt in America, why healthcare costs what it does, and what happened to the American dream.